Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV003180509 | SCV003881829 | likely benign | Inborn genetic diseases | 2023-01-26 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV003638920 | SCV004403789 | benign | Rubinstein-Taybi syndrome due to EP300 haploinsufficiency | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003420604 | SCV004114873 | uncertain significance | EP300-related disorder | 2024-08-22 | no assertion criteria provided | clinical testing | The EP300 c.1972C>A variant is predicted to result in the amino acid substitution p.Leu658Ile. This variant has been reported in an individual undergoing whole exome sequencing for myelomeningocele (Table S3, Au et al. 2021. PubMed ID: 33574475). This variant is reported in 0.0056% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |